Market openNon-fractionalADR
Mesoblast/MESO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Mesoblast
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
Ticker
MESO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
Headquarters
Melbourne, Australia
Employees
83
Website
www.mesoblast.com
Mesoblast Metrics
BasicAdvanced
$843M
Market cap
-
P/E ratio
-$1.44
EPS
3.47
Beta
-
Dividend rate
Price and volume
Market cap
$843M
Beta
3.47
52-week high
$10.24
52-week low
$1.61
Average daily volume
48
Financial strength
Current ratio
2.715
Long term debt to equity
21.743
Total debt to equity
23.981
Interest coverage (TTM)
-3.01%
Management effectiveness
Return on assets (TTM)
-10.92%
Return on equity (TTM)
-14.49%
Return on investment (TTM)
-11.67%
Valuation
Price to revenue (TTM)
112.92
Price to book
0.742
Growth
3-year revenue growth
-38.44%
What the Analysts think about Mesoblast
Analyst Ratings
Majority rating from 2 analysts.
Mesoblast Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q2 24
QoQ growth
Revenue
$3.3M
57.14%
Net income
-$33M
48.40%
Profit margin
-984.84%
-5.56%
Mesoblast Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.24
-$0.30
-$0.26
-$0.28
-
Expected
-$0.33
-$0.28
-$0.33
-$0.31
-$0.32
Surprise
-26.53%
7.14%
-21.69%
-9.68%
-
Mesoblast News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractionalADR
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Mesoblast stock?
Mesoblast (MESO) has a market cap of $843M as of July 05, 2024.
What is the P/E ratio for Mesoblast stock?
The price to earnings (P/E) ratio for Mesoblast (MESO) stock is 0 as of July 05, 2024.
Does Mesoblast stock pay dividends?
No, Mesoblast (MESO) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Mesoblast dividend payment date?
Mesoblast (MESO) stock does not pay dividends to its shareholders.
What is the beta indicator for Mesoblast?
Mesoblast (MESO) has a beta rating of 3.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Mesoblast stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.